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Purpose: To investigate the effect of R2* modeling in conventional 
and accelerated measurements of skeletal muscle fat 
fraction in control subjects and patients with muscular 
dystrophy.
Materials and 
Methods:
Eight patients with Becker muscular dystrophy and eight 
matched control subjects were recruited with approval 
from the Newcastle and North Tyneside 2 Research Ethics 
Committee and with written consent. Chemical-shift 
images with six widely spaced echo times (in 3.5-msec 
increments) were acquired to correlate R2* and muscle 
fat fraction. The effect of incorporating or neglecting R2* 
modeling on fat fraction magnitude and variance was eval-
uated in a typical three-echo protocol (with 0.78-msec 
increments). Accelerated acquisitions with this protocol 
with 3.653, 4.943, and 6.423 undersampling were re-
constructed by using combined compressed sensing and 
parallel imaging and fat fraction maps produced with R2* 
modeling.
Results: Muscle R2* at 3.0 T (33–125 sec21) depended on the mor-
phology of fat replacement, the highest values occurring 
with the greatest interdigitation of fat. The inclusion of 
R2* modeling removed bias, which was greatest at low fat 
fraction, but did not increase variance. The 95% limits of 
agreement of the accelerated acquisitions were tight and 
not degraded by R2* modeling (1.65%, 1.95%, and 2.22% 
for 3.653, 4.943, and 6.423 acceleration, respectively).
Conclusion: Incorporating R2* modeling prevents systematic errors in 
muscle fat fraction by up to 3.5% without loss of precision 
and should be incorporated into all muscular dystrophy 
studies. Fat fraction measurements can be accelerated 
fivefold by using combined compressed sensing and paral-
lel imaging, modeling for R2* without loss of fidelity.
q RSNA, 2015
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Muscular dystrophies are a het-erogeneous group of genetic diseases characterized by pro-
gressive muscle weakness and wasting. 
Over the course of the disease, skeletal 
muscle is progressively replaced by fat 
and fibrosis. There are currently no cu-
rative treatments, but several therapeu-
tic approaches for Duchenne muscular 
dystrophy, the most common form of 
muscular dystrophy, have entered clin-
ical trials (1). The primary end points 
of these trials are presently based on 
assessments of muscle function and 
strength, but these tests depend on 
patient motivation and engagement. 
Quantitative magnetic resonance (MR) 
chemical-shift imaging techniques, on 
the other hand, allow accurate, objec-
tive fat fraction analysis of muscle fat 
replacement (2) and are starting to be 
specified as trial end points. Quantita-
tive MR imaging has been applied in 
cross-sectional cohort studies (3–9) 
and longitudinal studies of disease pro-
gression (10,11) to measure muscle fat 
Implications for Patient Care
 n Volumetric muscle fat fraction 
measurements with R2* mod-
eling can be significantly acceler-
ated with combined compressed 
sensing and parallel imaging re-
construction, reducing imaging 
cost and patient burden in mus-
cular dystrophy clinical trials.
 n In clinical trials of muscular dys-
trophy, investigators who use MR 
imaging as an outcome measure 
need to model for R2* relaxation 
rate to eliminate bias in fat 
fractions.
Advances in Knowledge
 n MR imaging fat fraction measure-
ments in muscular dystrophy can 
be prospectively highly acceler-
ated to save time with modeling 
of R2* relaxation (95% limits of 
agreement, 1.65%, 1.95%, and 
2.22% for 3.653, 4.943, and 
6.423 accelerations, 
respectively).
 n Neglecting R2* modeling leads to 
protocol-dependent inaccuracy in 
fat fraction, which is a strong 
function of the fat fraction (the 
difference in fat fraction obtained 
when neglecting R2* modeling 
has a slope of 20.053 and an 
intercept of 3.41, both P , .001).
 n Modeling R2* relaxation in dys-
trophic muscle does not increase 
the variance of the calculated fat 
fraction compared with the un-
derlying physiological variance 
(ratio of fat fraction standard 
deviation calculated with R2* 
modeling compared with no R2* 
modeling is 0.95 6 0.19 [not 
significant]).
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fraction, and multicenter trial protocols 
have been issued (12).
Despite the increasing number of 
studies in muscular dystrophy, none 
of these model the effects of R2* re-
laxation (the reciprocal of T2*) on 
the fat fraction (3–7,10–12), though 
investigators in two studies have used 
a global R2 relaxation correction (8,9) 
extrapolated from values measured in 
control muscle. It has generally been 
assumed that R2* is relatively low 
compared with the echo times used 
and does not change greatly in these 
slow-progressing diseases; however, 
this has not been specifically evalu-
ated, even in those studies, by using 
multipeak fat modeling (6,8,9). This 
situation possibly arises because the 
research groups performing the clini-
cal studies in muscular dystrophy are 
distinct from those who developed the 
algorithms to compute fat fractions 
that incorporate R2*, who concen-
trated on the quantification of hepatic 
steatosis (13–15). When measuring fat 
fraction in the liver by using gradient-
echo sequences, it is recognized that 
iron overload can alter R2* by more 
than an order of magnitude (16) but 
that increasing diffuse hepatic steato-
sis without iron overload is not associ-
ated with R2* change where multipeak 
models of lipid are used (13).
Recently, fivefold accelerated acqui-
sition of whole-muscle fat fraction data 
has been demonstrated in muscular 
dystrophy, combining compressed sens-
ing and parallel imaging reconstruction 
(17) but not modeling R2* relaxation. 
These techniques have the ability to 
save expensive imaging unit time, im-
prove patient compliance (important for 
children), and make the incorporation 
of quantitative MR imaging into trial 
protocols more feasible. In our study, 
we considered the effect of incorporat-
ing R2* modeling when reconstructing 
fat fraction maps from accelerated im-
aging. We considered the relationship 
between fat fraction and R2* in healthy 
volunteers and patients with muscular 
dystrophy, illustrating the origins of R2* 
change in muscular dystrophy and the 
effect on fat fraction measurements in 
clinical trials, where multipeak models 
of lipid are used. The aim of our study 
was to investigate the effect of R2* 
modeling in conventional and acceler-
ated measurements of skeletal muscle 
fat fraction in control subjects and pa-
tients with muscular dystrophy.
Materials and Methods
Patients
Eight subjects (necessarily all men; 
mean age 6 standard deviation, 31 
years 6 12; age range, 21–56 years; 
weight, 76 kg 6 15; body mass in-
dex, 25 kg/m2 6 4) with a genetically 
proven diagnosis of Becker muscular 
dystrophy were recruited through the 
clinics of the Medical Research Council 
Centre for Neuromuscular Diseases at 
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Newcastle. Inclusion criteria included 
independent ambulation and no con-
traindications to MR imaging (eg, 
pacemaker, aneurysm clip, or claus-
trophobia). Eight age-matched healthy 
male control subjects (mean age, 
32 years 6 12; range, 21–55 years; 
weight, 78 kg 6 9; body mass index, 
24 kg/m2 6 4) were also recruited. 
The study, performed between May 
2013 and April 2014, obtained a fa-
vorable opinion from the Newcastle 
and North Tyneside 2 Research Ethics 
Committee, with all subjects giving 
written informed consent. K.G.H. had 
control of the study data. Some of the 
data obtained from the eight patients 
with Becker muscular dystrophy have 
been analyzed previously without R2* 
modeling (17) in a technical study that 
concentrated on optimizing parame-
ters in the reconstruction of the under-
sampled data: The overlap is detailed 
in the following subsections. Subjects 
lay supine, and their legs and feet were 
immobilized. D.M.H., an employee of 
Philips Healthcare, provided specialist 
advice to K.G.H. on reprogramming 
the MR imaging unit to perform un-
dersampling. K.G.H., an employee of 
Newcastle University, had complete 
control of and responsibility for the 
modifications to the imaging system, 
data acquisition, processing, and study 
inclusion.
Relationship between R2* and Fat 
Fraction of Dystrophic and Control Muscle
A 3.0-T Philips Achieva and six-channel 
cardiac coil (Philips, Best, the Nether-
lands) were used. A three-dimensional 
gradient-echo acquisition was used for 
patients with Becker muscular dystro-
phy and control subjects, with a matrix 
size of 256 read 3 190 phase 3 48 sec-
tions, field of view of 320 mm (right-left) 
3 190 mm (anterior-posterior) 3 240 
mm (foot-head) (or 285-mm anterior-
posterior for four larger subjects), and 
resolution of 1.25 3 1 3 5 mm (or 1.25 
3 1.5 3 5 mm). Six unipolar echoes 
per repetition time were acquired, with 
repetition time of 22 msec and echo 
times of 2.0, 5.5, 9.0, 12.5, 16.0, and 
19.5 msec; flip angle, 5°; receiver band-
width, 111 kHz; and acquisition time, 
198 seconds. The widely spaced echo 
times used (with 3.5-msec increments) 
allowed accurate characterization of a 
wide range of R2* values and water-fat 
separation. Two imaging blocks were 
acquired: The first was centered in the 
mid-lower leg, defined as the part of the 
calf muscle with the largest circumfer-
ence, and the second was in the thigh, 
determined by locating the superior 
border of the patella, and the anterior 
superior iliac spine, centering one-third 
of the distance superior to the patella. 
Data were acquired from patients and 
control subjects for both legs with the 
read direction left-right.
The chemical-shift separation into 
water and fat images was performed 
by using the “graphcut” algorithm pre-
viously described by Hernando et al 
(18,19) with a single R2* component. 
This algorithm was robust to water/fat 
swapping when using wide echo spac-
ing. It should be noted that we only 
proposed to model one R2* compo-
nent, and it is more generally true that 
the fat and water present in a pixel may 
have independent R2* values. However, 
it has been shown for liver steatosis 
measurement that modeling two inde-
pendent components led to instability 
and noise breakthrough in the resulting 
fat fraction maps and that the remain-
ing bias in a one-component fit was 
small (20,21), even if the R2* of water 
and fat species were markedly differ-
ent. A six-component fixed-spectrum 
model was used to represent fat (22). 
Proton-density fat fraction maps were 
generated, avoiding noise bias (23). 
By using ImageJ (National Institutes of 
Health, Bethesda, Md), regions of in-
terest (ROIs) were drawn by K.G.H. on 
10 axial sections per anatomic area at 
midsection on the left leg. The areas 
delineated at these levels included the 
tibialis anterior, soleus, medial and lat-
eral gastrocnemius muscles, and bone 
marrow of the tibia, as a structure com-
posed principally of fat. In the thigh, 
we outlined the rectus femoris, vastus 
lateralis, vastus intermedius, biceps fe-
moris long head, semitendinosus, semi-
membranosus, and sartorius muscles. 
The regions were defined on the sum of 
the water and fat images. The mean fat 
fractions and R2* relaxation rates were 
evaluated and averaged for each muscle 
group for each subject, providing 192 
data points for a comparative plot. The 
mean fat fractions and R2* relaxation 
rates of the healthy control subjects 
and patients with Becker muscular dys-
trophy were tested for significance by 
using a Mann-Whitney U test, for both 
individual muscles and overall.
Intrarater (repeatability) and inter-
rater (reproducibility) variation of the 
ROI analysis was assessed in all regions 
of four randomly chosen patients with 
Becker muscular dystrophy. T.L. and 
K.G.H. marked and evaluated all the 
regions independently; K.G.H. addi-
tionally made a further marking of all 
the ROIs 3 weeks later without refer-
ence to his original regions. In both 
cases, Bland-Altman analysis (24) was 
used to evaluate the bias and 95% 
limits of agreement between the paired 
fat fractions and R2* values.
Comparison of Fat Fractions Evaluated 
with and without R2* Modeling
A further three-dimensional spoiled gra-
dient-echo stack was acquired in the 
patients and control subjects by using 
the field of view and matrix size de-
tailed earlier, with three interleaved 
gradient echoes with narrow echo spac-
ing (0.78-msec increments) to optimize 
the fat fraction measurement (repeti-
tion time of 10 msec and echo times of 
4.40, 5.18, and 5.96 msec; flip angle, 
3°; one echo acquired per repetition 
time; bandwidth, 55.5 kHz; and acqui-
sition time, 273 seconds). Such narrow 
echo spacing is typical of protocols used 
in muscular dystrophy studies (3–11).
Fat fraction maps were produced by 
using the algorithm of Tsao and Jiang 
(19,25), a fast algorithm robust for fat 
water separation with narrow echo time 
spacing, with the same fat model and 
noise bias correction as given earlier, 
both with and without single component 
R2* compensation. ROI analysis was 
performed as detailed earlier. A Bland-
Altman plot was constructed for the dif-
ference in fat fraction with and without 
R2* modeling and the mean fat fraction 
for all muscle groups. For comparisons 
of differences in fat fraction for specific 
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Figure 1
Figure 1: Plot of R2* relaxation rate versus fat fraction for all ROIs in the lower and upper 
legs of the control subjects (squares) and patients with Becker muscular dystrophy (BMD) 
(circles). Note that tibial bone marrow regions have fat fraction close to 100% for both con-
trol subjects and patients. See Figure 2 for more information on data points A–G.
muscle groups, a Wilcoxon paired test 
was used.
To determine whether the vari-
ance of fat fraction with R2* modeling 
exceeded that without R2* modeling, 
we calculated the ratio of the standard 
deviations of fat fraction for each ROI, 
derived from the 10 axial sections. If 
the extra variance in fat fraction from 
incorporating R2* modeling predicted 
for uniform tissue (14) was significant 
over the natural physiological variation, 
the ratio would be significantly greater 
than 1. The ratios were tested for sig-
nificant deviation from unity by using a 
two-tailed F test. The data from the pa-
tients with Becker muscular dystrophy 
only has previously been analyzed with-
out R2* modeling for reconstruction 
optimization (17).
Accelerated Fat Fraction Measurements 
with Combined Compressed Sensing and 
Parallel Imaging Reconstruction and R2* 
Modeling
Prospectively accelerated data were 
acquired from the patients with Beck-
er muscular dystrophy by using a cus-
tom modified three-dimensional spoiled 
gradient-echo pulse program with 
variable-density Poisson disk unders-
ampling, as detailed previously, to omit 
phase encodes (17), depicted in Figure 
E1 (online). Three echoes with narrow 
echo spacing (0.78-msec increments) 
were used, as in the previous section. 
Data with net accelerations of 3.653, 
4.943, and 6.423 were acquired pro-
spectively. The acceleration factors 
were determined through choosing 
three different minimum mean sepa-
rations of k-space points in the sam-
pling pattern; the same undersampling 
pattern was used for each echo time. 
The undersampled acquisition times 
were 75 seconds, 55 seconds, and 43 
seconds, respectively. A coherent (reg-
ular) 3.363 undersampling for recon-
struction with parallel imaging only 
was also acquired.
The undersampled data were re-
constructed with combined compressed 
sensing and parallel imaging (26), 
where the optimization of the algo-
rithm parameters required has been 
demonstrated in detail previously 
(17), summarized in Appendix E1 (on-
line). Fat-water separation involved 
use of the algorithm of Tsao and Jiang 
(19,25) with single-component R2* 
modeling. The data from the patients 
with Becker muscular dystrophy were 
previously processed (17) without R2* 
modeling to demonstrate reconstruc-
tion optimization.
The fat fractions generated by the 
reconstructions from undersampled 
data were compared with those from 
the fully sampled data with stan-
dard reconstruction (inverse Fourier 
transform and phase-sensitive coil 
combination). By using Bland-Altman 
analysis (24), measures of bias and the 
95% limits of agreement between the 
measurements were calculated.
Results
The Relationship between R2* and Fat 
Fraction of Dystrophic and Control Muscle
The R2* relaxation rates plotted against 
the fat fraction of each muscle group 
for the patients with Becker muscu-
lar dystrophy and control subjects are 
shown in Figure 1, with representa-
tive proton-density fat fraction and 
R2* maps shown in Figure 2. The R2* 
value increased and then decreased 
again as fat fraction increased from 
0% to 100%. Note that tibial bone 
marrow has fat fraction close to 100% 
for control subjects and patients. For 
control muscles (the letter A on Fig 
2) and patient muscles with no fat 
replacement, the R2* was approxi-
mately 40 sec21. The mean fat frac-
tion and R2* (6 standard deviation) 
for control subject muscles were 3.2% 
6 1.2 and 41.5 sec21 6 3.8 and for 
patients were 39.4% 6 35.4 and 54.2 
sec21 6 16.6, respectively (both P , 
.001 compared with control subjects). 
In dystrophic muscle with substantial 
interdigitation of fat and water, R2* 
was increased: In the thigh of a pa-
tient with Becker muscular dystrophy, 
especially high values of R2* occurred 
in the semimembranosus (the letter B 
on Fig 2, 90.5 sec21) and biceps femo-
ris long head (the letter C on Fig 2, 
128.1 sec21), where there was a highly 
diffuse pattern of fat infiltration. The 
highest R2* in the lower leg muscles 
(the letter D on Fig 2, 83.0 sec21) 
was seen in a lateral gastrocnemius 
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Figure 2
Figure 2: Proton-density fat fraction maps in black and white with accompanying R2* maps for the 
midthigh and lower leg of a control subject and selected patients with Becker muscular dystrophy show the 
effect of fat infiltration on R2* value. Muscles giving rise to certain data points in Figure 1 are indicated by 
capital letters (A–G).
with diffuse fat infiltration. Similar 
patterns of interdigitated fat and sig-
nificantly elevated R2* were seen in 
the vastus intermedius (the letter E 
on Fig 2, 85.8 sec21) and vastus lateralis 
of another patient (the letter F on Fig 2, 
81.5 sec21).
Once the fat replacement increased 
beyond approximately 75%, the fat ap-
peared as a continuous area, and the 
R2* decreased once more (such as the 
letter G on Fig 2, 59.9 sec21, where 
the lateral and medial gastrocnemii 
have been completely replaced by fat). 
The R2* of muscles mostly replaced by 
fat, bone marrow, and subcutaneous 
fat tended toward 40 sec21 or lower 
(Fig 1). With 192 data points from 16 
individuals, there will be within-pa-
tient correlation especially in control 
subjects, though the muscle groups of 
patients with Becker muscular dystro-
phy can show marked variation.
The repeatability assessment of 
fat fraction showed a negligible bias 
between the two occasions (0.04%, 
not significant), and the 95% limit of 
agreement was 1.40% (20.4 sec21 
and 2.0 sec21 for R2*, respectively). 
The reproducibility assessment again 
shows negligible bias between the two 
analysts (0.04%, not significant), and 
the 95% limit of agreement was 1.52% 
(20.03 sec21 and 2.8 sec21 for R2*, 
respectively).
Comparison of Fat Fractions Evaluated 
with and without R2* Modeling
Figure 3 shows the fat fractions for the 
patients with Becker muscular dystro-
phy derived with R2* compensation 
compared with those derived without, 
presented against the line of equality 
(Fig 3, A) and as a Bland-Altman plot 
(Fig 3, B). The overall trend was that 
neglecting R2* modeling led to overesti-
mation of fat fraction at low fat fraction 
by as much as 3.5%, but the effect dis-
appeared at moderate fat fractions with 
underestimation at high fat fraction. 
Table 1 shows the effect of R2* model-
ing for the muscles that we highlighted 
in Figure 1. While Figure 3, B, shows 
nonlinear differences for fat fractions 
close to 0% or 100%, a regression to 
the linear portion of the plot (between 
10% and 90%) yields y = 20.0527x + 
3.41 (both coefficients, P , .001). The 
effect on the fat fraction was most sig-
nificant for the lowest fat fraction (the 
letter A on Fig 2) with an R2* value of 
36.4 sec21 (P , .005), where there was 
2.3% overestimation. The muscle group 
with the highest R2* observed (the let-
ter C on Fig 2) showed no significant 
difference in fat fraction whether R2* 
was modeled or not.
The mean ratio of the standard de-
viation of fat fraction within each ROI 
with R2* fitting compared with no R2* 
fitting was 0.95 6 0.19 (F test results, 
not significant), indicating that the fit-
ting of the extra parameter did not sig-
nificantly increase the variance of fat 
fraction within an ROI compared with 
the underlying physiological variability 
in the measurement, as has been theo-
retically demonstrated for uniform tis-
sue (14). R2* modeling can be added 
to the precision of the resulting fat 
fractions in muscular dystrophy with-
out substantial cost.
Accelerated Fat Fraction Measurements 
with Combined Compressed Sensing and 
Parallel Imaging Reconstruction and R2* 
Modeling
Figure 4 shows an example of the recon-
structed fat fraction images for two pa-
tients with muscular dystrophy, showing 
a high quality of reconstruction with R2* 
modeling with combined compressed 
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Table 1
Fat Fractions Measured without and with R2* Fitting and the R2* Value for the Muscle 
Groups Illustrated in Figures 1 and 2
Muscle R2* (sec-1)
Fat Fraction without  
R2* Modeling (%)
Fat Fraction with  
R2* Modeling (%)
Difference in  
Fat Fraction (%) P Value
A 36.4 3.8 1.5 2.3 .005
B 90.5 27.0 25.9 1.1 .005
C 128.1 66.8 66.7 0.1 NS
D 83.0 52.5 51.5 1.0 NS
E 85.8 62.0 61.3 0.7 .007
F 81.5 73.7 75.2 1.5 .005
G 59.9 82.5 83.9 1.4 .005
Note.—The P value shows the significance associated with the difference in fat fraction by using a Wilcoxon paired test. NS = 
not significant. The muscle groups A–G are annotated in Figures 1 and 2.
Figure 3
Figure 3: A, Data plot and, B, Bland-Altman plot are used to compare proton-density fat frac-
tions without R2* fitting versus fat fractions with R2* fitting. BMD = Becker muscular dystrophy.
sensing and parallel imaging, while Fig-
ure E2 (online) shows difference images. 
Table 2 summarizes the fat fractions, 
gathered by muscle group, for the patients 
with Becker muscular dystrophy for full 
sampling and accelerated measurements, 
showing means and standard deviations 
in very close agreement. Fat fraction data 
from the fully sampled control data are 
given for reference. The fat fractions in 
healthy muscle groups vary, owing to 
their internal structures (for example, 
compare the fat fraction of the tibialis 
anterior with that of the soleus muscle). 
A further breakdown of the data is pro-
vided in Table E1 (online). Figure E3 (on-
line) shows the complete Bland-Altman 
plots that were used to compare the fat 
fractions measured from the accelerated 
data with the fully sampled data. Table 
3 summarizes the Bland-Altman data, 
showing that there was no significant bias 
and that the 95% limits of agreement 
were tight and not significantly worse 
than those calculated without R2* model-
ing calculated previously (17), while R2* 
modeling improves the accuracy of the 
fat fractions. The full Bland-Altman plots 
are available as Figure E2 (online). The 
accelerated acquisitions reconstructed 
with combined compressed sensing and 
parallel imaging provided a true measure 
of the fat fraction.
Discussion
In our study, we demonstrated the pat-
tern of changing R2* due to fat replace-
ment in dystrophic skeletal muscle by 
using a multipeak lipid model, taking 
Becker muscular dystrophy as a repre-
sentative disease, which provided mus-
cle fat fractions across the full dynamic 
range (0%–100%). In control muscle, 
R2* values were reasonably constant 
and on the order of 35–45 sec21, in 
agreement with previous literature (27). 
Similar R2* values were found in mus-
cle that has been completely replaced 
by fat, subcutaneous fat, and tibial bone 
marrow. The morphologic arrangement 
of the fat replacing the muscle had a pro-
found influence on the R2* values; those 
muscles with midrange fat fractions and 
highly striated fat replacement showed 
the greatest increases in R2* compared 
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Figure 4
Figure 4: Fat fraction maps in two patients with Becker 
muscular dystrophy were generated from data acquired with 
full sampling and 3.653, 4.943, and 6.423 accelerated 
acquisition.
with control subjects. This stood in 
marked contrast to measurements in 
diffuse hepatic steatosis, where, for pa-
tients unaffected by hepatic iron over-
load, R2* was independent of the degree 
of steatosis (13), provided that a multi-
peak lipid model was used.
As demonstrated, not modeling for 
R2* relaxation introduced bias, which 
was particularly acute at low values of 
fat fraction, where the greatest over-
estimation occurred. This bias will be 
dependent on the choice of echo times 
and field strength used, preventing 
comparison between study sites where 
identical acquisition conditions cannot 
be used. This point has not been previ-
ously recognized in muscular dystrophy 
research studies, where it has been as-
sumed that R2* is low and that effects 
of not modeling R2* on fat fraction are 
negligible. Our study shows that it is 
the muscles with low R2* values at low 
fat fractions that generate the largest 
errors, while the highest muscle R2* 
values tend to lie in a fat fraction region 
that is least sensitive to R2* correction. 
This has important implications for the 
measurement of early stage disease and 
indicates that R2* correction should be 
performed routinely.
For midrange fat fractions, the effect 
of R2* correction was modest, and the 
conclusions of previous cross-sectional 
cohort and longitudinal disease pro-
gression studies are likely to be correct, 
since the change in the fat striations is 
generally small between longitudinal time 
points. The largest overestimations, and 
indeed differences in calculated fat frac-
tion if R2* changes, will occur in control 
muscle and dystrophic muscles with low 
fat fractions. Since we have shown that 
modeling R2* does not increase the var-
iance of the fat fraction measurements 
on a practical ROI basis, it should not 
affect the precision of longitudinal mea-
surements and should always be used. 
Moreover, the fact that structures that 
contain only water or fat had an effective 
R2* of 35–45 sec21 means that making 
a global correction based on R2 values 
(as performed in references 8 and 9) of 
fat and water from a control subject, ap-
proximately 6.7 sec21 and 26.3 sec21 at 
3.0 T, respectively, is likely to produce 
systematic errors in fat fraction. R2* 
modeling will benefit harmonization in 
multicenter trials, where echo times and 
field strengths used may vary.
The bounds of agreement between 
the fully sampled data and the acceler-
ated data were similar to those with-
out R2* compensation (17), and, taken 
together with improved fat fraction 
accuracy and no loss of precision, rep-
resent an improvement on that study. 
Our previous study also demonstrated 
that the intrinsic image quality of the 
undersampled reconstructions permit-
ted all ROIs to be distinguished up to 
4.943 acceleration but that at the high-
er acceleration (6.423), not all desired 
ROIs could be delineated. Such an ac-
celeration reduces the time to acquire 
volumes covering both upper and lower 
legs with 48 sections of 5-mm thick-
ness from a total of 9 minutes to less 
than 2 minutes. The total unaccel-
erated acquisition time is similar to 
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Table 3
Findings of Bland-Altman Analysis to Compare the Fat Fractions Derived from ROIs 
in the Fully Sampled Data and the Undersampled Data in the Patients with Becker 
Muscular Dystrophy by Modeling a Single R2* Component
Reconstruction
Bias Compared with Fully  
Sampled Reconstruction (%)
95% Limit of Agreement Compared  
with Fully Sampled Reconstruction (%)
Compressed sensing and parallel  
imaging 3.653
20.05 1.65
Compressed sensing and parallel  
imaging 4.943
20.13 1.95
Compressed sensing and parallel  
imaging 6.423
0.17 2.22
Parallel imaging 3.363 0.21 2.99
Table 2
Mean Fat Fraction of the Different Muscle Groups and Bone Marrow Averaged for the Eight Patients with Becker Muscular Dystrophy 
and Eight Control Subjects with R2* Modeling
ROI
Patients with Becker Muscular Dystrophy
Control SubjectsFull (%) 3.653 (%) 4.943 (%) 6.423 (%)
Bone marrow 99.4 6 0.4 99.3 6 0.3 99.3 6 0.3 99.4 6 0.4 99.4 6 0.2
Biceps femoris long head 76.7 6 29.7 77.0 6 29.7 76.8 6 30.0 76.9 6 30.1 3.5 6 1.9
Semimembranosus 68.7 6 34.8 68.9 6 35.0 68.9 6 34.9 69.2 6 34.8 3.8 6 1.8
Semitendinosus 59.9 6 38.4 59.9 6 38.4 59.7 6 38.4 60.0 6 38.2 3.5 6 1.9
Vastus intermedius 47.8 6 29.7 47.8 6 30.0 48.3 6 30.2 48.4 6 29.8 2.6 6 0.9
Medial gastrocnemius 47.2 6 31.0 47.3 6 31.1 47.2 6 31.3 47.4 6 31.1 3.0 6 1.1
Vastus lateralis 43.6 6 28.2 43.3 6 28.7 43.7 6 28.6 44.4 6 28.2 3.0 6 0.8
Rectus femoris 32.8 6 28.4 32.5 6 28.2 31.8 6 28.1 32.3 6 27.8 1.9 6 0.8
Lateral gastrocnemius 28.4 6 32.8 27.8 6 32.9 27.7 6 32.7 28.1 6 32.5 2.2 6 0.7
Sartorius 20.0 6 30.3 20.7 6 30.6 19.7 6 30.9 20.4 6 30.6 6.1 6 2.6
Soleus 13.8 6 10.2 13.4 6 9.9 13.1 6 9.9 13.4 6 9.6 4.3 6 1.6
Tibialis anterior 4.2 6 2.0 4.1 6 1.9 4.0 6 1.9 4.1 6 1.6 2.3 6 0.8
Note.—Data are means 6 standard deviations.
two-dimensional protocols that cover 25 
sections of 5-mm thickness (8,9). The 
ability to highly accelerate MR imaging 
fat fraction measurements in dystrophic 
muscle has the potential to decrease 
MR imaging trial costs, increase pa-
tient compliance, and decrease patient 
movement artifacts, particularly where 
children are studied. In general, it may 
make the acquisition of MR imaging end 
points more acceptable within the con-
text of a clinical trial.
The limitations of our study included 
the fact that our fat fraction measure-
ments have not been validated with bi-
opsy, but this was not routinely clinically 
indicated for our patients, and hepatic 
proton-density chemical-shift techniques 
with multipeak lipid modeling and R2* 
fitting have already been shown to have 
excellent agreement with biopsy results 
(28). While a modest number of pa-
tients were studied, the heterogeneity of 
fat replacement between muscle groups 
permitted the full dynamic range of the 
technique to be studied. Our measure of 
fat fraction variance, based on 10 axial 
sections covering 50 mm of muscle in 
the foot-head direction, reflects common 
practice in clinical trials of averaging sev-
eral results from adjacent sections to re-
duce longitudinal sensitivity to small vari-
ations in patient position. Within-subject 
correlation was not dealt with in this 
analysis. For that reason, the presented 
robust-test inference might be slightly 
more optimistic. In the accelerated acqui-
sitions, only three echoes were collected, 
one per repetition time interval. This has 
been found to be sufficient in liver stud-
ies by using R2* fitting and multipeak fat 
modeling (13) and permitted close echo 
spacing (0.78 msec) for accurate B0 field 
map determination. The qualitative fea-
sibility of an alternative approach to ac-
celerating fat-water separation with R2* 
modeling has been demonstrated in the 
skeletal muscle of a control subject (29). 
While there have been skeletal muscle 
studies with reports of fat fraction in 
type 2 diabetes, spina bifida, and rota-
tor cuff injuries that have modeled R2* 
(27,30,31), in none of these studies was 
dystrophic muscle considered or was a 
particular significance ascribed to the R2* 
values obtained. Owing to the nonmono-
tonic relationship of R2* relaxation rates 
with disease progression, R2* is unlikely 
to be a useful trial end point, though it is 
essential for estimating fat fractions.
In summary, our study demonstrated 
that R2* varies during fat replacement in 
the muscular dystrophy disease process, 
and R2* variation needs to be accounted 
for in fat fraction analysis. Furthermore, 
inclusion of an R2* modeling term in ei-
ther fully sampled or highly accelerated 
fat fraction measurements does not de-
grade the precision.
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